Trial intelligence / Profile preview

Phase 3 randomized double-blind placebo-controlled study of venetoclax plus azacitidine in previously untreated AML patients ineligible for standard induction therapy

MOH_2017-08-16_000263Phase 3Completed

Sponsor

AbbVie Inc.

Start

May 2017

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Countries

1